ライフサイエンスコーパス: lactosylceramide

1 ommon fungal receptors, such as dectin-1 and lactosylceramide.

2 osynthesis of most complex gangliosides from lactosylceramide.

3 D3, GM4 > GM1, GD1a, GD1b, GT1b, GD2, GQ1b > lactosylceramide.

4 ion, and the levels of the glycosphingolipid lactosylceramide.

5 ng a fluorescent sphingolipid analog, BODIPY-lactosylceramide.

6 d in neural tissue, by adding sialic acid to lactosylceramide.

7 by converting GM2 to GA2 and subsequently to lactosylceramide.

8 1-3)-glucans and by a monoclonal antibody to lactosylceramide.

9 m human leukocytes and its identification as lactosylceramide, a major glycosphingolipid of neutrophi

10 tion of the GM3 synthase enzyme (also called lactosylceramide alpha-2,3 sialyltransferase).

11 (globotriaose and isoglobotriaose) and alpha-lactosylceramide (alpha-LacCer).

12 bcellular localization of ST3GalV (CMP-NeuAc:lactosylceramide alpha2,3 sialyltransferase/GM3 synthase

13 atly reduced levels of GM3 and GM3 synthase (lactosylceramide alpha2,3-sialyltransferase) mRNA in bot

14 utant mice that lack GM3 synthase (CMP-NeuAc:lactosylceramide alpha2,3-sialyltransferase; EC 2.4.99.-

15 was accompanied by a decrease in the mass of lactosylceramide and an increase in glucosylceramide (Gl

16 abnormal intracellular trafficking of BODIPY-lactosylceramide and an increase of sterols in the cultu

17 estoration of Golgi targeting of fluorescent lactosylceramide and endogenous GM(1) ganglioside, and a

18 orescent analogues of the glycosphingolipids lactosylceramide and globoside almost exclusively by a c

19 bstrate clone 15, we found that analogues of lactosylceramide and globoside were internalized almost

20 biosynthetic derivatives and an increase in lactosylceramide and its alternative derivatives.

21 a lesser extent, inhibited the formation of lactosylceramides and gangliosides.

22 Most prominently lactosylceramide, and additionally ceramide, glucosylcer

23 nd sphingomyelin but normal hexosylceramide, lactosylceramide, and different sphingosines compared wi

24 h ceramide, sphingomyelin, glucosylceramide, lactosylceramide, and ganglioside G(D3) (a composition s

25 sulfated glycosphingolipids sulfatide, sulf-lactosylceramide, and sulf-globopentaosylceramide.

26 ils, myeloblasts expressed glucosylceramide, lactosylceramide, and the neolacto-family GSLs, lactotri

27 ganisms, this represents the first report of lactosylceramide binding to a macromolecular carbohydrat

28 bstrates, GM3-BODIPY-FL, GM1-BODIPY-TMR, and lactosylceramide-BODIPY-650/665.

29 ructures of apo-GLTP (1.65 A resolution) and lactosylceramide-bound (1.95 A) GLTP, in which the bound

30 g it to GA2 and further hydrolysis of GA2 to lactosylceramide by HexB with the assistance of mouse GM

31 w that addition of the glycosphingolipid, C8-lactosylceramide (C8-LacCer), or free cholesterol to hum

32 We used a fluorescent analogue of lactosylceramide, called N-[5-(5,7-dimethylborondipyrrom

33 hile phosphatidylethanolamine, ceramide, and lactosylceramide cannot.

34 on by the exogenous addition of GM3, but not lactosylceramide, caused enhanced c-Src phosphorylation

35 ected against the membrane glycosphingolipid lactosylceramide (CDw17) results in a significant decrea

36 decreased levels of ceramide, sphingomyelin, lactosylceramide, ceramide trihexoside, and globoside an

37 However, DL-lactosylceramides containing dihydrosphingosine did not

38 tion of 12 Ga2 isoforms/analogues from their lactosylceramide counterparts, was developed and validat

39 otein-2 (MIP-2) from isolated AECs through a lactosylceramide-dependent mechanism.

40 Lactosylceramides from human leukocytes were fractionate

41 zed as galactosylceramide, glucosylceramide, lactosylceramide, galabiaosylceramide, globotriaosylcera

42 Both transferases act on lactosylceramide, Galbeta1,4Glcbeta1Cer (LacCer), to pro

43 osylceramide, the monosialoganglioside, GM3, lactosylceramide, globoside, the disialoganglioside, GD3

44 In particular, lactosylceramide, globotriaosylceramide (Gb3), and monos

45 amide, glucosylceramide, galactocerebroside, lactosylceramide, globotriaosylceramide, and the ganglio

46 y) LC/MS identified substantial increases in lactosylceramide in AB-/- mouse livers.

47 knockout mice show a massive accumulation of lactosylceramide in all tissues.

48 DO-P4 depleted cellular glucosylceramide and lactosylceramide in cultured ECV304 cells at nanomolar c

49 The levels of glucosylceramide and lactosylceramide increased in parallel with Gb3 levels i

50 Since lactosylceramide (LacCer) accumulates in large quantitie

51 n the endocytosis of BODIPYtrade mark-tagged lactosylceramide (LacCer) analogs via caveolae.

52 Lactosylceramide (LacCer) and globotriaosylceramide (Tri

53 lation increased the intracellular levels of lactosylceramide (LacCer) and induced GFAP expression an

54 atment increased the intracellular levels of lactosylceramide (LacCer) and induced iNOS gene expressi

55 aposin C led to moderate increases in GC and lactosylceramide (LacCer) and their deacylated analogues

56 ere incubated with a fluorescent analogue of lactosylceramide (LacCer) at 16 degrees C to label early

57 Previously, our laboratory has shown that lactosylceramide (LacCer) can serve as a mitogenic agent

58 In addition, fluorescent lactosylceramide (LacCer) colocalized with DsRed-cav-1 i

59 Lactosylceramide (LacCer) is a key intermediate in glyco

60 Lactosylceramide (LacCer) is a pivotal intermediate in t

61 we found that glucosylceramide (GlcCer) and lactosylceramide (LacCer) levels are significantly highe

62 Previously, our laboratory reported that lactosylceramide (LacCer) stimulated human aortic smooth

63 Here we report that lactosylceramide (LacCer) synthesized by beta-1,4-galact

64 Minor storage of lactosylceramide (LacCer) was observed when compared wit

65 A fluorescent analog of lactosylceramide (LacCer) was used to study plasma membr

66 We have previously reported that lactosylceramide (LacCer), a ubiquitous GSL, stimulates

67 fluorescent glycosphingolipid analog, BODIPY-lactosylceramide (LacCer), and compared this to fluoresc

68 Glucosylceramide (GlcCer), lactosylceramide (LacCer), and globotriaosylceramide (Gb

69 tein gp120 (rgp120) with natural isolates of lactosylceramide (LacCer), glucosylceramide (GlcCer), an

70 of mhtt inhibited internalization of BODIPY-lactosylceramide (LacCer), which is internalized by a ca

71 by the co-analysis of its structural isomer, lactosylceramide (LacCer), which is not an alpha-GAL A s

72 nied with a 32-fold increase in the level of lactosylceramide (LacCer).

73 iGb(3) synthase acts on lactosylceramide, LacCer (Galbeta1,4Glcbeta1Cer) to form

74 cholesterol levels and a 3-fold increase in lactosylceramide levels.

75 ficantly decreased renal neuraminidase 1 and lactosylceramide levels.

76 declining activity of the regulatory enzyme lactosylceramide N-acetylglucosaminyltransferase (GlcNAc

77 The enzymes studied were lactosylceramide: N-acetylglucosaminyl transferase (GlcN

78 oated plates through interaction of GM3 with lactosylceramide or Gg3, whereby not only adhesion but a

79 containing glycolipid (galactosylceramide or lactosylceramide) or from monosialoganglioside dispersio

80 nt presence of ganglioside GM3 and adhere to lactosylceramide- or Gg3-coated plates through interacti

81 alactosidase functions in the degradation of lactosylceramide preferentially in the liver.

82 of the anti-CDw17 antibody with solubilized lactosylceramide reverses this effect.

83 Lactosylceramide specifically induced c-fos mRNA express

84 We found that lactosylceramide stimulated (7-fold) the loading of GTP

85 -galactosidase activities than HBEC, whereas lactosylceramide synthase (GalT2) activity was higher in

86 gmented, ceramide glucosyltransferase (CGT), lactosylceramide synthase (GalT2), Gb3 synthase (GalT6),

87 n inhibitor of glucosylceramide synthase and lactosylceramide synthase (LCS: beta-1,4-GalT-V), showed

88 amide synthase activities but did not affect lactosylceramide synthase activities or mRNA content.

89 n, Ca(2+) deposits, and glucosylceramide and lactosylceramide synthase activity.

90 e (D2); (C). reduced expression 3 gene; (D). lactosylceramide synthase; and (E). septin 4, respective

91 nd that application of the glycosphingolipid lactosylceramide to CLN3-deficient cells rescues protein

92 The binding of radiolabeled PGG-glucan to lactosylceramide was not inhibited by glycogen, dextran,

93 nding of radiolabeled PGG-glucan to purified lactosylceramide was saturable, specific, and time- and

94 (D1a), was the most active molecule, whereas lactosylceramide was the least active one, indicating re